Latest SR ONE CAPITAL MANAGEMENT, LP Stock Portfolio
SR ONE CAPITAL MANAGEMENT, LP Performance:
2025 Q4: 3.2%YTD: 37.52%2024: -0.43%
Performance for 2025 Q4 is 3.2%, and YTD is 37.52%, and 2024 is -0.43%.
About SR ONE CAPITAL MANAGEMENT, LP and 13F Hedge Fund Stock Holdings
On 2026-02-12, the fund reported it's updated stock portfolio. In the 13F Holdings report, SR One Capital Management, LP reported an equity portfolio of $706.4 Millions as of 31 Dec, 2025.
The top stock holdings of SR One Capital Management, LP are , ACLX, CRSP. The fund has invested 25.9% of it's portfolio in ZENAS BIOPHARMA, INC and 21.7% of portfolio in ARCELLX, INC.
They significantly reduced their stock positions in MINERALYS THERAPEUTICS INC.. SR One Capital Management, LP opened new stock positions in ULTRAGENYX PHARMACEUTICAL INC. (RARE). The fund showed a lot of confidence in some stocks as they added substantially to OCULIS HOLDING AG.
The top stock holdings of SR One Capital Management, LP are , ACLX, CRSP. The fund has invested 25.9% of it's portfolio in ZENAS BIOPHARMA, INC and 21.7% of portfolio in ARCELLX, INC.
They significantly reduced their stock positions in MINERALYS THERAPEUTICS INC.. SR One Capital Management, LP opened new stock positions in ULTRAGENYX PHARMACEUTICAL INC. (RARE). The fund showed a lot of confidence in some stocks as they added substantially to OCULIS HOLDING AG.
SR ONE CAPITAL MANAGEMENT, LP Annual Return Estimates Vs S&P 500
Our best estimate is that SR One Capital Management, LP made a return of 3.2% in the last quarter. In trailing 12 months, it's portfolio return was 37.52%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| ultragenyx pharmaceutical inc. | 3,168,320 |
New stocks bought by SR ONE CAPITAL MANAGEMENT, LP
Additions
| Ticker | % Inc. |
|---|---|
| oculis holding ag | 98.77 |
| zenas biopharma, inc | 2.57 |
Additions to existing portfolio by SR ONE CAPITAL MANAGEMENT, LP
Reductions
| Ticker | % Reduced |
|---|---|
| mineralys therapeutics inc. | -26.02 |
SR ONE CAPITAL MANAGEMENT, LP reduced stake in above stock
Sold off
Sector Distribution
SR One Capital Management, LP has about 52.1% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 52.1 |
| Others | 41.3 |
| 6.6 |
Market Cap. Distribution
SR One Capital Management, LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- SMALL-CAP
| Category | % |
|---|---|
| UNALLOCATED | 41.3 |
| MID-CAP | 37.2 |
| SMALL-CAP | 20.6 |
Stocks belong to which Index?
About 36.5% of the stocks held by SR One Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 63.5 |
| RUSSELL 2000 | 36.5 |
SR ONE CAPITAL MANAGEMENT, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of SR ONE CAPITAL MANAGEMENT, LP
SR One Capital Management, LP has 13 stocks in it's portfolio. About 97.7% of the portfolio is in top 10 stocks. ACLX proved to be the most loss making stock for the portfolio. was the most profitable stock for SR One Capital Management, LP last quarter.
Last Reported on: 12 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx, inc. | 21.66 | 2,346,630 | 153,000,000 | unchanged | 0.00 | ||
| CRSP | crispr therapeutics ag | 15.13 | 2,038,760 | 106,913,000 | unchanged | 0.00 | ||
| DSGN | design therapeutics, inc. | 8.67 | 6,526,480 | 61,218,300 | unchanged | 0.00 | ||
| NKTX | nkarta, inc. | 0.87 | 3,333,330 | 6,166,670 | unchanged | 0.00 | ||
| ORIC | oric pharmaceuticals, inc. | 5.34 | 4,514,930 | 37,753,800 | unchanged | 0.00 | ||
| RARE | ultragenyx pharmaceutical inc. | 0.45 | 137,753 | 3,168,320 | new | |||
| SBTX | ars pharmaceuticals, inc. | 6.62 | 4,012,900 | 46,750,300 | unchanged | 0.00 | ||
| zenas biopharma, inc | 25.90 | 5,037,850 | 182,924,000 | added | 2.57 | |||
| mineralys therapeutics inc. | 8.04 | 1,563,970 | 56,756,300 | reduced | -26.02 | |||
| alumis inc. | 2.71 | 1,959,900 | 19,128,600 | unchanged | 0.00 | |||
| oruka therapeutics, inc | 1.85 | 430,330 | 13,043,300 | unchanged | 0.00 | |||
| oculis holding ag | 1.81 | 641,022 | 12,801,200 | added | 98.77 | |||
| engene holdings inc. | 0.96 | 747,750 | 6,752,180 | unchanged | 0.00 | |||